RecruitingNot ApplicableNCT05285553

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms


Sponsor

CooperVision, Inc.

Enrollment

900 participants

Start Date

Jun 25, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.


Eligibility

Min Age: 8 YearsMax Age: 12 Years

Inclusion Criteria15

  • Informed Consent and Assent have been completed
  • Be between 8 and 12 years of age inclusive at the time of enrollment.
  • Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.75 D and -4.00 D inclusive (at the corneal plane) in each eye
  • Best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.
  • Anisometropia: ≤ 1.50D SERE.
  • Astigmatism: ≤ 0.75 D
  • Free of ocular disease or abnormalities (including any corneal scar)
  • Currently have good general health.
  • Agree to accept the lens as assigned by the randomization.
  • Be capable of comprehending the nature of the study and be willing and able to adhere to the instructions set forth in this protocol.
  • Ability to comply with study procedures, including high and low (sub-study only) contrast high and low (sub-study only) lighting visual acuity, axial length, and cycloplegic auto-refraction measurements taken for both eyes.
  • Able to maintain the visit schedule.
  • Willingness to participate in the trial for 4 years.
  • Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week.
  • Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.

Exclusion Criteria22

  • Current or prior use of any pharmaceuticals or other methods for control of myopia, such as bifocals, progressive addition lenses, orthokeratology, atropine, pirenzepine or any other myopia control treatment.
  • Use of any systemic or topical ocular medications or over-the-counter artificial tears which might interfere with contact lens wear, pupil size, accommodation or refractive state, or require the lenses to be removed during the day.
  • Previously worn or currently wears rigid gas permeable contact lenses, including orthokeratology lenses
  • Has any of the following specific contraindications to MiSight 1 Day lenses at Baseline Visit:
  • Acute and subacute inflammation or infection of the anterior chamber of the eye.
  • Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids.
  • Severe insufficiency of lacrimal secretion (dry eyes).
  • Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic.
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.
  • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions.
  • Any active corneal infection (bacterial, fungal, or viral).
  • If eyes are red or irritated.
  • The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so.
  • Has history of:
  • Corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
  • Giant papillary conjunctivitis
  • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses
  • A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.
  • Corneal hypoesthesia (reduced corneal sensitivity)
  • Keratoconus or an irregular cornea.
  • Strabismus or amblyopia.
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMiSight 1 Day

Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.

DEVICEProclear 1 day

Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years. Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year.


Locations(30)

University of Alabama School of Optometry

Birmingham, Alabama, United States

Marshall B. Ketchum University Southern California College of Optometry

Fullerton, California, United States

Vision Solutions Optometry Inc

La Mesa, California, United States

Paje Optometric

Santa Ana, California, United States

Coan Eye Care and Optical Boutique

Ocoee, Florida, United States

West Broward Eyecare Associates

Tamarac, Florida, United States

Bright Eyes Family Vision Care

Tampa, Florida, United States

SoLo Eye Care & Eyewear Gallery

Chicago, Illinois, United States

Illinois College of Optometry

Chicago, Illinois, United States

Chicago College of Optometry

Downers Grove, Illinois, United States

Carillon Vision Care

Glenview, Illinois, United States

Brain Vision Institute

Schaumburg, Illinois, United States

Clinical Optics Research Lab at IU School of Optometry

Bloomington, Indiana, United States

Kannarr Eye Care

Pittsburg, Kansas, United States

New England College of Optometry

Boston, Massachusetts, United States

Cornea and Contact Lens Institute

Edina, Minnesota, United States

Vision Source EyeCare

Kansas City, Missouri, United States

Athens Eye Care

Athens, Ohio, United States

Ohio State University

Columbus, Ohio, United States

ProCare Vision Center, Inc.

Granville, Ohio, United States

Miamisburg Vision Care

Miamisburg, Ohio, United States

Eye Care Professionals

Powell, Ohio, United States

Southern College of Optometry

Memphis, Tennessee, United States

Texas State Optical

Beaumont, Texas, United States

University of Houston College of Optometry

Houston, Texas, United States

Vision One Eyecare

Katy, Texas, United States

Lone Star Vision

Plano, Texas, United States

Utah Eye Centers

Ogden, Utah, United States

Virginia Pediatric Eye Care

Chesapeake, Virginia, United States

Factoria Eye Clinic

Bellevue, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05285553


Related Trials